The document provides an overview of the pharmaceutical industry in India. It discusses the current state and growth of the industry. Some of the key points include:
- The Indian pharmaceutical industry is large and growing at 8-9% annually, currently worth $4.5 billion.
- Major players in the industry include Cipla, Ranbaxy, Dr. Reddy's, Sun Pharma, and Aurobindo Pharma.
- The government has introduced several initiatives to support the industry such as allowing 100% FDI and establishing a $639 million venture capital fund.
- The industry faces challenges of declining R&D productivity, patent expirations, and pricing issues but is expected
Status of pharmaceutical industry in indiaShadab Khan
Status of Pharmaceutical Industry in India
-History
-Evolution
-Current Scenario
-Market Share
-Government Initiatives
-Top 10 Pharmaceutical Industry
-R&D Spendings
-Challenges
-Road Ahead
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Status of pharmaceutical industry in indiaShadab Khan
Status of Pharmaceutical Industry in India
-History
-Evolution
-Current Scenario
-Market Share
-Government Initiatives
-Top 10 Pharmaceutical Industry
-R&D Spendings
-Challenges
-Road Ahead
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Public sector undertakings of pharma in IndiaSai Datri Arige
It is about the pharmaceutical companies in India which are directly headed by government of India and about the pioneers of Indian pharmaceutical industry, which max concentrate on growth of Indian Pharmaceutical Industry
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Future of the Global Pharmaceutical IndustryTim Opler
Key points in presentation from Torreya Partners.
Despite concerns regarding research productivity and pricing pressure, Torreya is optimistic about the pharma sector. There is huge growth ahead driven by expanding global wealth.
The global pharma sector is going to at least triple in scale between now and 2060.
The pharmaceutical sector is 30% larger than shown by prior data.
New technologies in manufacture, biologics, nucleic acids and implantables will dramatically alter the pharma sector.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Public sector undertakings of pharma in IndiaSai Datri Arige
It is about the pharmaceutical companies in India which are directly headed by government of India and about the pioneers of Indian pharmaceutical industry, which max concentrate on growth of Indian Pharmaceutical Industry
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Future of the Global Pharmaceutical IndustryTim Opler
Key points in presentation from Torreya Partners.
Despite concerns regarding research productivity and pricing pressure, Torreya is optimistic about the pharma sector. There is huge growth ahead driven by expanding global wealth.
The global pharma sector is going to at least triple in scale between now and 2060.
The pharmaceutical sector is 30% larger than shown by prior data.
New technologies in manufacture, biologics, nucleic acids and implantables will dramatically alter the pharma sector.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
National and international status of pharma indus.Priyesh Pandya
The pharmaceutical industry is responsible for the development, production and marketing of medications.
The industries is expected to register growth led by aging population, changing lifestyles, hectic daily activities, unhealthy eating, increasing incidence of chronic diseases across the global population providing growth opportunities for the industry players.
Prescription drug sales expected to reach $1.18trn in 2024.
Pharmaceutical industry
Overview of industry
The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications.
Pharmaceutical companies may deal in generic or brand medications and medical devices.
Global Players of Industry
Johnson & Johnson
With nearly US$71.89 billion more in revenue, Johnson & Johnson is by far the world’s largest pharmaceutical company based on revenue.
Pfizer (US$52.82bn)
In second place, American biopharmaceutical company Pfizer has moved up two places from last year. The company focuses on a wide range of therapy areas including oncology, neuroscience, metabolic diseases and rare disease, as well as developing vaccines.
Roche (US$50.11bn)
In the top three pharmaceutical companies of 2017 is another Swiss-based pharma, Roche. The company develops drugs and diagnostic instruments and has a presence in Europe, North America, South America and Asia.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Indian pharmaceuticals-industry (1)
1. A BRIEF REPORT PHARMACEUTICAL INDUSTRY IN INDIA
March, 2012
2. 1. OVERVIEW OF PHARMACUETICAL INDUSTRY
1.1. An Introduction
The Indian pharmaceutical industry currently tops the chart amongst India's science-based
industries with wide ranging capabilities in the complex field of drug manufacture and
technology. A highly organized sector, the Indian pharmaceutical industry is estimated to be
worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high amongst all the
third world countries, in terms of technology, quality and the vast range of medicines that are
manufactured. It ranges from simple headache pills to sophisticated antibiotics and complex
cardiac compounds, almost every type of medicine is now made in the Indian pharmaceutical
industry.
The Indian pharmaceutical sector is highly fragmented with more than 20,000 registered units. It
has expanded drastically in the last two decades. The Pharmaceutical and Chemical industry in
India is an extremely fragmented market with severe price competition and government price
control. The Pharmaceutical industry in India meets around 70% of the country's demand for
bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals
and injectibles. There are approximately 250 large units and about 8000 Small Scale Units, which
form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).
The Government has also played a vital role in the development of the India Software Industry.
In 1986, the Indian government announced a new software policy which was designed to serve
as a catalyst for the software industry. This was followed in 1988 with the World Market Policy
and the establishment of the Software Technology Parks of India (STP) scheme. In addition, to
attract foreign direct investment, the Indian Government permitted foreign equity of up to 100
percent and duty free import on all inputs and products.
1.2 Current Scenario
India's pharmaceutical market grew at 15.7 per cent during December 2011. Globally, India
ranks third in terms of manufacturing pharma products by volume. The Indian pharmaceutical
industry is expected to grow at a rate of 9.9 % till 2010 and after that 9.5 % till 2015. The Indian
pharmaceutical market is expected to touch US$ 74 billion sales by 2020 from US$ 11 billion.
The market has the further potential to reach US$ 70 billion by 2020 in an aggressive growth
scenario.
Moreover, the increasing population of the higher-income group in the country will open a
potential US$ 8 billion market for multinational companies selling costly drugs by 2015. Besides,
the domestic pharma market is estimated to touch US$ 20 billion by 2015, making India a
lucrative destination for clinical trials for global giants.
Further estimates the healthcare market in India to reach US$ 31.59 billion by 2020.
3. 12.1. Diagnostics Outsourcing/Clinical Trials
According to the estimates, the Indian diagnostics and labs test services, in view of its growth
potential, is expected to reach Rs159.89 billion by FY2013. The Indian market for both
therapeutic and diagnostic antibodies is expected to grow exponentially in the coming years.
Findings from the report suggest that more than 60% of the total antibodies market is currently
dominated by diagnostic antibodies.
Some of the major Indian pharmaceutical firms, including Sun Pharma, Cadilla Healthcare and
Piramal Life Sciences, had applied for conducting clinical trials on at least 12 new drugs in 2010,
indicating a growing interest in new drug discovery research.
1.2.2 Generics
India tops the world in exporting generic medicines worth US$ 11 billion and currently, the
Indian pharmaceutical industry is one of the world's largest and most developed.
Moreover, the Indian generic drug market to grow at a CAGR of around 17 per cent between
2010-11 and 2012-13. Union Minister of Commerce and Industry and Minister for Trade and
Industry, Singapore, have signed a 'Special Scheme for Registration of Generic Medicinal
Products from India' in May 2010, which seeks to fast-track the registration process for Indian
generic medicines in Singapore.
1.3 Advantage India
The Indian Pharmaceutical Industry, particularly, has been the front runner in a wide range of
specialties involving complex drugs' manufacture, development and technology. With the
advantage of being a highly organised sector, the pharmaceutical companies in India are growing
at the rate of $ 4.5 billion, registering further growth of 8 - 9 % annually.
More than 20,000 registered units are fragmented across the country and reports say that 250
leading Indian pharmaceutical companies control 70% of the market share with stark price
competition and government price regulations.
Competent workforce: India has a pool of personnel with high managerial and technical competence
as also skilled workforce. It has an educated work force and English is commonly used.
Professional services are easily available.
Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved
cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide
variety of bulk drugs and exports sophisticated bulk drugs.
Legal & Financial Framework: India has a 53 year old democracy and hence has a solid legal
framework and strong financial markets. There is already an established international industry
and business community.
Information & Technology: It has a good network of world-class educational institutions and
established strengths in Information Technology.
4. Globalisation: The country is committed to a free market economy and globalization. Above all, it
has a 70 million middle class market, which is continuously growing.
Consolidation: For the first time in many years, the international pharmaceutical industry is finding
great opportunities in India. The process of consolidation, which has become a generalized
phenomenon in the world pharmaceutical industry, has started taking place in India.
5. 2 MAJOR PHARMACEUTICAL COMPANIES IN INDIA
Some of the leading Indian players by sales (US$ million)
Company name Sales in US$ million Year End
Cipla 6,368.06 March 2011
Ranbaxy Lab 5,687.33 December 2010
Dr Reddy's Labs 5,285.80 March 2011
Sun Pharma 1,985.78 March 2011
LupinLtd 4,527.12 March 2011
Aurobindo Pharma 4,229.99 March 2011
Piramal Health 1,619.74 March 2011
Cadila Health 2,213.70 March 2011
Matrix Labs 1,894.30 March 2010
Wockhardt 651.72 December 2011
2.1 Ranbaxy
Ranbaxy is among the predominant pharmaceutical companies in India and was founded in 1961.
Ranbaxy is a research based pharma giant and became a public limited company in 1973.
Ranbaxy was recently ranked among the top 10 international pharmaceutical companies in the
world have presence across 49 countries.
Ranbaxy is also reputed for its 11 state-of-the-art manufacturing facilities in countries like China,
India, Brazil, South Africa, and Nigeria. The company has also won several awards and
recognitions for its pioneering initiatives in the developing markets of the world. Ranbaxy is also
a member of the Indian Pharmaceutical Alliance and Organization of Pharmaceutical Producers
of India. In the present scenario Ranbaxy commands more than 5% share of the Indian
pharmaceutical market. Ranbaxy’s product portfolio is diverse and includes drugs that cater to
nutrition, infectious diseases, gastro-enteritis, pain management, cardiovascular ailments,
dermatology, and central nervous system related ailments.
Ranbaxy’s operations in India are designed under as many as 9 SBUs which take care of the
various categories of medicines and drugs that are manufactured by Ranbaxy. The company is
especially well-known for having the highest research and development (R&D) budget among
pharma companies in the world which is as high as US$ 100 million.
Ranbaxy India operations are handled by 2,500 employees and the company’s market share in
India is worth around US$6 billion.
2.2 Dr. Reddy's Laboratories
Dr. Reddy's Laboratorie is one of the popular pharmaceutical companies with base in more than
100 countries. The medicines of Dr. Reddy's Laboratories Limited are easily available all across
the globe.
6. Dr. Reddy's Pharmaceutical Company is very much customer friendly. It takes care of the fact
that maximum people get benefited by the products of this pharmaceutical company. It
commercialized various treatments so as to provide high tech treatment to the masses. It tries to
meet the medical needs of the people.
Though Dr. Reddy's Laboratories is located in various parts of the world, it has its headquarters
in India. The subsidiaries of this company are found at various countries like US, Germany, UK,
Russia and Brazil. 16 countries have the representative offices of Dr. Reddy's Laboratories
Limited. 21 countries have third party distribution.
2.3 Cipla
Cipla was founded by Khwaja Abdul Hamied in 1935 and was known as The Chemical,
Industrial and Pharmaceutical Laboratories, though it is better known by the acronym Cipla
today. Cipla was registered in August, 1935 as a public limited enterprise and it began with an
authorized capital of Rs. 6 lakh.
Though set up in 1935, it was only in 1937 that Cipla began manufacturing and marketing its
pharmaceutical products. Today, the company has its facilities spread across several locations
across India such as Mumbai, Goa, Patalganga, Kurkumbh, Bangalore, and Vikhroli.
Apart from its strong presence in the Indian market, Cipla also has an extensive export market
and regularly exports to more than 150 countries in regions such as North America, South
American, Asia, Europe, Middle East, Australia, and Africa. For the year ended 31st March,
2007 Cipla’s exports were worth approximately Rs. 17,500 million. Cipla is also considerably
well-known for its technological innovation and processes for which the company received
know-how loyalties to the tune of Rs. 750 million during 2006-07.
2.4 Sun Pharmaceuticals
Sun Pharmaceuticals was set up in 1983 and the company started off with only 5 products to
cure psychiatric illness. Sun Pharma is known worldwide as the manufacture of specialty Active
Pharmaceuticals Ingredients and formulations.
However, the company is also concerned with chronic treatments such as cardiology, psychiatry,
neurology, gastroenterology, diabetology, and respiratory ailments. Active Pharmaceuticals
Ingredients (API) include peptides, steroids, hormones, and anti-cancer drugs and their quality is
internationally approved. The international offices of Sun Pharmaceuticals Industries Ltd. are
located in British Virgin Islands, Russia, and Bangladesh. In India, the offices are in Vapi,
Silvassa, Panoli, Ahmednagar, and Chennai.
There are 3 major group companies of Sun Pharmaceuticals Industries are:
Caraco Pharmaceuticals Laboratories (based in Detroit, Michigan)
Sun Pharmaceuticals Industries Inc. (Michigan)
Sun Pharmaceuticals (Bangladesh)
7. 2.5 Aurobindo Pharma
Aurobindo Pharma, an India-based private pharmaceutical company having presence around the
world. Aurobindo Pharma was set up in the year 1986 and started its operations in 1988-89 in
Pondicherry, India. Now, the company is headquartered at Hyderabad, India.
Aurobindo Pharma is one of the most respected generic pharmaceuticals and active
pharmaceutical ingredients (API) manufacturing company of the world. Aurobindo Pharma
operates in over 100 countries across the world. Further, the pharmaceutical major markets over
180 APIs and 250 formulations throughout these destinations. This Indian pharmaceutical major
has filed over 110 DMFs and 90 ANDAs for the USA market. So far, Aurobindo has received
45 ANDA approvals (both final and tentative) from USA alone.
Aurobindo Pharma products cover segments like –
Antibiotics,
Anti-Retro Virals
CVS
CNS
Gastroenterological
Anti-Allergics
8. 3 GOVERNMENT INITIATIVES AND INVESTMENT
3.1 Government Initiative
100 per cent foreign direct investment (FDI) is allowed under the automatic route in the drugs
and pharmaceuticals sector including those involving use of recombinant technology. (DIPP)
The Government plans to set up a US$ 639.56 million venture capital (VC) fund to give a boost
to drug discovery and strengthen the pharma infrastructure in the country.
The Government had issued an expression of interest (EoI) for technical and financial bids for
the selection of a global level consultant (GLC) for the preparation of a detailed project report
(DPR) in order to develop India as a drug discovery and pharma innovation hub by 2020. The
Drugs and Pharmaceuticals Manufacturers Association has received an in-principle approval for
its proposed special economic zone (SEZ) for pharmaceuticals, bulk drugs, active
pharmaceutical ingredients (APIs) and formulations to be located at Nakkapalli mandal in
Visakhapatnam district.
The Department of Pharmaceuticals has prepared a "Pharma Vision 2020" for making India one
of the leading destinations for end-to-end drug discovery and innovation and for that purpose
provides requisite support by way of world class infrastructure, internationally competitive
scientific manpower for pharma research and development (R&D), venture fund for research in
the public and private domain and such other measures.
The government plans to open 3,000 Jan Aushadhi stores, which sell unbranded generic drugs at
heavy discounts to branded drugs, in the next two years.
3.2 Investment
The healthcare sector has attracted growing investor support in 2010 with nearly a tenth of the
total private equity funding going to this sector. In the third quarter the calendar year 2010, a
total of US$ 2,047 million was invested across 88 deals, of which 9 per cent were healthcare
deals.
The pharma, healthcare and biotech sector witnessed five merger and acquisition transactions
(M&A) worth US$ 250 million.
The drugs and pharmaceuticals sector has attracted FDI worth US$ 1,825.43 million between
April 2000 and September 2010.
Some of the major investment developments in the sector include:
Hyderabad-based Natco Pharma plans to raise US$ 22.22 million to fund its expansion plans
and research activities.
Private equity major Sequoia Capital has made its first investment in the pharmaceutical
sector in the country by investing US$ 15.86 million into Celon Labs, which will use the
funds to double its manufacturing facility.
9. Belgium based Helvoet Pharma, part of the Daetwyler Group is setting up its first greenfield
production facility in Khandala Industrial Area, phase I (SEZ), on Pune- Bangalore Highway,
near Pune. The company has invested US$ 26.56 million for the plant.
Swiss Pharma major Lonza AG, would invest around US$ 55.33 million through its Indian
subsidiary in a phased manner in Genome Valley project, Hyderabad, said Stefan Borgas,
CEO, Lonza.
Chennai-based Bafna Pharmaceuticals plans to raise around US$ 4.43 million for its future
expansion by issuance of warrants and shares.
Hyderabad Menzies Air Cargo Private Limited, a joint venture between GMR Hyderabad
International Airport Limited (GHIAL) and Menzies Aviation, has launched India's first
airport-based pharma zone, dedicated pharmaceutical cargo storage and handling facility, at
Hyderabad. The project involved an investment of US$ 1.22 million.
10. 4 CHALLENGES & FUTURE GROWTH
4.1 Challenges
Over the past decade, pharmaceutical companies have entered a difficult period where
shareholders, the market and regulators have created significant pressures for change within the
industry. The core issues for most of drug companies are declining productivity of in-house R &
D, patent expiration of number of block buster drugs, increasing legal and regulatory concern,
and pricing issue. As a result larger pharmaceutical companies are shifting to new business
model with greater outsourcing of discovery services, clinical research and manufacturing.
Current global financial conditions and the threat of a broad recession accelerated the timetable
for implementing transformational changes in global organizations, as the industry confronts
lower corporate stock prices and an increasingly cost-averse customer. Leaders of the largest
global pharmaceutical companies recognize the need for transformational change in their
organizations, but will need to move swiftly to ensure sustained growth.
Transformations in the business model of larger pharmaceutical industry spell more
opportunities for Indian pharmaceutical companies. Pharmaceutical production costs are almost
50 percent lower in India than in western nations, while overall R&D costs are about one-eighth
and clinical trial expenses around one-tenth of western levels.
The Indian stock market may be dreading a possible recession but Indian pharma companies
seem unfazed by slowdown fears. Riding on better sales in the domestic and export markets,
Indian pharmaceutical industry is expected to continue with its good performance.
Today Indian pharmaceutical Industry can look forward to the years to come, with great
expectations. There are opportunities in expanding the range of generic products as more
molecule come off patent, outsourcing, and above all, in focusing into drug discovery as more
profits come from traditional plays. At the same time, the Indian Pharma Industry would have to
contend with several challenges particularly the
Effects of new product patent
Drug price control
Regulatory reforms
Infrastructure development
Quality management and
Conformance to global standards.
4.2 Growth
The Indian pharmaceutical market reached US$ 10.04 billion in size, with a value-wise growth
rate of 20.4 per cent over the previous year’s corresponding period on a Moving Annual Total
(MAT) basis for the 12 months ended July 2010.
Cipla maintained its leadership position in the domestic market with 5.27 per cent share,
followed by Ranbaxy. The highest growth in the domestic market was for Mankind Pharma,
11. which grew 37.2 per cent. Leading companies in the domestic market such as Sun Pharma (25.7
per cent), Abbott (25 per cent), Zydus Cadila (24.1 per cent), Alkem Laboratories (23.3 per cent),
Pfizer (23.6 per cent), GSK India (19 per cent), Piramal Healthcare (18.6 per cent) and Lupin
(18.8 per cent) had impressive growth during July 2010, shows the data.
The pharmaceuticals industry in India will grow by over 100 per cent over the next two years.
The pharmaceutical industry is currently growing at the rate of 12 per cent, but this will
accelerate soon. The sale of all types of medicines in the country stands at US$ 9.61 billion,
which is expected to reach around US$ 19.22 billion by 2012.
India's domestic pharmaceutical market is valued approximately at US$ 12 billion in 2010, and
has shown a strong growth of 21.3 per cent for the 12 months ending September 2010. It
estimates that over the next 10 years, the domestic market will grow to US$ 49 billion, at a
compounded annual growth rate (CAGR) of 15 per cent.
The formulations industry is expected to prosper parallel to the pharmaceutical industry. It is
expected that the domestic formulations market in India will grow at an annual rate of around 17
per cent in 2009-10, owing to increasing middle class population and rapid urbanisation.